Revvity, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Revvity, Inc. is a life sciences and diagnostics company that provides health science solutions, technologies, expertise, and services delivering comprehensive workflows from discovery to development, diagnosis, and cure. The company offers instruments, reagents, assay platforms, software, detection and imaging technologies, and automated solutions such as liquid handlers and cell counters. Its product portfolio includes specialized brands like AlphaLISA and SureFire Ultra no-wash assays, Cellometer and Celigo automated cell counters, chemagic nucleic acid extraction systems, IVIS fluorescence and bioluminescence imaging platforms, LentiBOOST for lentiviral transduction, Vanadis noninvasive prenatal testing systems, and various other reagents, consumables, and assay kits targeting life science research and clinical diagnostics markets. Revvity’s diagnostics segment focuses on reproductive health, immunodiagnostics, applied genomics, and infectious disease detection, serving hospitals, medical labs, clinicians, and research professionals globally. Founded in 1937 and headquartered in Waltham, Massachusetts, Revvity emerged in 2023 following the split of PerkinElmer, Inc., retaining the life sciences and diagnostics businesses while the remaining segments were sold to private equity. Since its spinoff, Revvity has undergone significant strategic restructuring, including reorganizing its operating model effective fiscal year 2025 to integrate its Applied Genomics business into a newly formed Life Sciences Solutions unit. The company re-segmented its operations into Life Sciences Solutions and Software, and Diagnostics, which now encompasses Immunodiagnostics and Reproductive Health. Recent innovations include the launch of AI-driven software platforms like Signals One, the IDS i20 ChLIA analyzer, and advanced imaging systems such as the Quantum GX3 targeting specialized diagnostics markets. Revvity actively pursues cost discipline and operational synergies while investing in digital transformation and AI integration to enhance productivity and competitive positioning in precision diagnostics and life sciences research. Revvity serves pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and clinical markets worldwide. Its comprehensive offerings support translational multi-omics technologies, biomarker identification, molecular imaging, immunoassays, molecular diagnostics, and genomic workflows with a focus on oncology, immunology, personalized medicine, and early disease detection. The company operates across North America, Europe, and other global regions, driven by innovation in reproductive health science, immune system disorder diagnostics, and genetic disorder testing. With a workforce exceeding 11,000 employees, Revvity continues to expand its product portfolio and technological capabilities to remain a leader in biotechnology, diagnostics, and life sciences markets.
Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One
Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
Revvity to Hold Earnings Call on Tuesday, August 4, 2026
Revvity Expands Signals AI With Anthropic Claude Integration
Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
Revvity Launches Signals AI to Advance Scientific R&D Workflows
Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay
Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution
RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution
Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript
Compared to Estimates, Revvity (RVTY) Q1 Earnings: A Look at Key Metrics
Revvity (RVTY) Q1 Earnings and Revenues Top Estimates
Revvity Announces Financial Results for the First Quarter of 2026
Revvity to Report Q1 Earnings: What's in Store for the Stock?
Revvity Board Declares Quarterly Dividend
Sumitomo Mitsui Trust Group Inc. Has $3.46 Million Stock Position in Revvity Inc. $RVTY